FDA 483 - Keystone Bioanalytical, Inc. - June 28, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Keystone Bioanalytical, Inc. in North Wales, PA, conducted from June 24-28, 2019, identified a significant issue regarding data integrity and quality control. The contract research organization failed to report all method validation data, specifically omitting results from LLOQ samples that, when included, demonstrated out-of-specification inter-batch precision. This indicates a failure to ensure the accuracy and reliability of their bioanalytical method validation processes.
ID · d5e38f0c-41df-4575-8624-37b5578f8450